Wegovy vs. Victoza

See how Wegovy and Victoza compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Wegovy (semaglutide) is FDA-approved for chronic weight management and cardiovascular risk reduction in adults with obesity, while Victoza (liraglutide) treats type 2 diabetes and its related cardiovascular risk.

  • Both drugs share a boxed warning for thyroid C-cell tumors and cause similar gastrointestinal side effects like nausea and diarrhea.

  • Wegovy is injected once a week at a higher maximum dose, while Victoza requires a daily injection at a lower maximum dose.

Wegovy vs. Victoza Drug Summary

Wegovy

Wegovy is a GLP-1 receptor agonist given as a once-weekly injection. It is FDA-approved for chronic weight management in adults and adolescents with obesity or overweight, and to lower cardiovascular risk in adults with heart disease and obesity. It is not approved for treating diabetes.

Victoza

Victoza is a GLP-1 receptor agonist given as a once-daily injection. It is FDA-approved to improve blood sugar control in adults and children with type 2 diabetes, and to lower cardiovascular risk in adults with diabetes and heart disease. It is not approved for weight management.

Wegovy vs. Victoza Side Effects

Wegovy

Most common
Nausea (up to 44%)
Diarrhea (up to 30%)
Constipation (up to 24%)
Vomiting (up to 24%)

Victoza

Most common
Nausea (up to 5%)
Diarrhea (up to 12%)
Constipation (up to 5%)
Vomiting (up to 5%)

Wegovy vs. Victoza Dosage

Wegovy

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2.4 mg once weekly Week 17 onward
Dose changes 4 increases Every 4 weeks

Victoza

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 1.8 mg once daily Week 3 onward
Dose changes 2 increases Every week

Wegovy vs. Victoza Indications

Wegovy

Wegovy is prescribed for long-term weight management alongside diet and exercise in people with obesity or a weight-related condition like high blood pressure. It also carries an indication to reduce the risk of heart attack, stroke, and cardiovascular death in adults with obesity and existing heart disease.

  • Chronic weight management in adults with obesity or overweight plus a related condition

  • Approved for adolescents 12 and older

  • Reduces risk of major cardiovascular events in adults with established heart disease

  • Used alongside diet and exercise

Victoza

Victoza is prescribed to improve blood sugar control in adults and children 10 and older with type 2 diabetes, used alongside diet and exercise. It also carries an indication to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and existing heart disease.

  • Glycemic control in adults and children 10 and older with type 2 diabetes

  • Reduces risk of major cardiovascular events in adults with type 2 diabetes and heart disease

  • Used alongside diet and exercise

  • Not approved for weight management

Wegovy vs. Victoza Pros and Cons

Wegovy

Wegovy's higher maintenance dose and weight-specific approval make it the more established option for chronic weight management, backed by cardiovascular outcomes data in people without diabetes. Insurance coverage for weight loss indications can still be inconsistent.

Pros

  • FDA-approved specifically for weight management, not just off-label use

  • Only needs one injection per week

  • Approved for adolescents as young as 12

Cons

  • Newer to market with less long-term real-world data than Victoza

  • Longer titration schedule before reaching maintenance dose

  • Not approved for treating type 2 diabetes

Victoza

Victoza has over a decade of real-world use for type 2 diabetes and a well-established safety record, including pediatric data. Its once-daily injection and lower maximum dose can mean smaller weight loss results if used off-label for that purpose.

Pros

  • Longer track record, on the market since 2010

  • Approved for children as young as 10 with type 2 diabetes

  • Simple three-step dose titration completed within weeks

Cons

  • Requires a daily injection instead of a once-weekly one

  • Not FDA-approved for weight management

  • Generally produces less weight loss than Wegovy at approved doses

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.